KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Treasury Shares (2020 - 2025)

Castle Biosciences (CSTL) has disclosed Treasury Shares for 6 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 6.24% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, up 6.24% year-over-year, with the annual reading at $3.4 million for FY2025, 6.24% up from the prior year.
  • Treasury Shares hit $3.4 million in Q4 2025 for Castle Biosciences, up from $350144.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.4 million in Q4 2025 to a low of $196033.0 in Q4 2022.
  • Historically, Treasury Shares has averaged $1.8 million across 5 years, with a median of $1.9 million in 2021.
  • Biggest five-year swings in Treasury Shares: crashed 81.33% in 2022 and later soared 1330.92% in 2023.
  • Year by year, Treasury Shares stood at $1.1 million in 2021, then plummeted by 81.33% to $196033.0 in 2022, then skyrocketed by 1330.92% to $2.8 million in 2023, then rose by 13.94% to $3.2 million in 2024, then grew by 6.24% to $3.4 million in 2025.
  • Business Quant data shows Treasury Shares for CSTL at $3.4 million in Q4 2025, $350144.0 in Q3 2025, and $3.2 million in Q4 2024.